Pharmacological Management of Parkinson's & Alzheimer's Disease | Part 2 | Medical Lecture

Added:

Limitations of Symptomatic Pharmacotherapy and the Shift to Disease-Modifying and Lifestyle Interventions

While traditional pharmacological management of Parkinson's and Alzheimer's focuses on symptomatic relief (such as replacing dopamine or inhibiting cholinesterase), a significant counter-perspective criticizes this paradigm for failing to address the underlying neurodegenerative pathology. Current medications do not halt disease progression and often lead to severe long-term side effects, such as levodopa-induced dyskinesia or cognitive fluctuations. The alternative viewpoint advocates for a dual shift: first, toward disease-modifying therapies (like gene therapy, monoclonal antibodies, and regenerative medicine) designed to stop cell death; and second, toward rigorous non-pharmacological interventions. Ample clinical evidence suggests that targeted physical exercise, cognitive rehabilitation, and dietary interventions (such as the Mediterranean-DASH Diet Intervention for Neurodegenerative Delay) can actively promote neuroplasticity, reduce neuroinflammation, and improve patient outcomes. This holistic approach challenges the reliance on purely chemical symptom management.

Pathophysiology of neurodegenerative disorders, specifically the degeneration of dopaminergic neurons in Parkinson's and cholinergic pathways in Alzheimer's.
Basic neuroanatomy and function of the basal ganglia and cerebral cortex.
The synthesis, release, receptor interaction, and enzymatic degradation of the neurotransmitters dopamine and acetylcholine.
Fundamental pharmacological principles, including the mechanism of blood-brain barrier penetration, drug receptor agonism, and enzyme inhibition.
Clinical management of long-term levodopa therapy complications, such as motor fluctuations (the 'on-off' phenomenon) and drug-induced dyskinesia.
Emerging disease-modifying therapies for Alzheimer's disease, including monoclonal antibodies targeting amyloid-beta and tau proteins.
Surgical interventions and device-assisted therapies for advanced Parkinson's disease, such as Deep Brain Stimulation (DBS) and levodopa-carbidopa intestinal gel.
Pharmacological management of non-motor symptoms of neurodegenerative diseases, including dementia-related psychosis, depression, and autonomic dysfunction.
33.5K views582likes2:25:09@DoctorNajeebOriginal Release: 2023-04-16

Levodopa, the primary treatment for Parkinson's disease, produces peripheral side effects (cardiovascular issues, GI disturbances) and central side effects (dyskinesias, psychiatric complications). Long-term use leads to response fluctuations including end-of-dose akinesia and on-off phenomenon due to progressive dopaminergic neuron loss. Management strategies include dopamine receptor agonists (pramipexole, ropinirole), MAO-B inhibitors (selegiline), COMT inhibitors (entacapone), and anticholinergics, with the goal of maintaining therapeutic dopamine levels while minimizing side effects.